MedTrace Logo

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NCT02495779 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

This study is designed to investigate the acceptability, perceived need and uptake of short-term episodic Pre-Exposure Prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM). The overall objective is to determine the feasibility of a clinic-based Epi-PrEP implementation pilot project for 50 MSM (25/each of the 2 study sites) who report occasional condomless sex and who anticipate a period of high-risk while away from home (e.g. vacation) during the study period.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

emtricitabine/tenofovir

Short-term episodic use for 2-3 weeks.

BEHAVIORAL

CBT-based counseling

Brief CBT-based counseling to promote adherence

Sponsors & Collaborators

  • Fenway Community Health

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • James Egan

    lead OTHER

Principal Investigators

  • Ronald D Stall, PhD, MPH · University of Pittsburgh

  • Kenneth Mayer, MD · Fenway Health

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495779 on ClinicalTrials.gov